Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (8)

Showing 1-8 of 8

Sorted By:

A-Z
Z-A

Previous Next

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases (ECLIPSE)
compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy according to physician's choice (control arm) in HNSCC.
A Study to Investigate the Efficacy of Durvalumab plus Tremelimumab in Combination with Chemotherapy
Efficacy of Durvalumab + Tremelimumab combined With Chemo vs Pembrolizumab combined With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)
Faeth_FTH-PIK-201: An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer
Ph 2 Trial Evaluating Sapanisertib&Serabelisib (PIKTOR) w/Paclitaxel & Substudy Eval. PIKTOR w/Paclitaxel + Insulin-Suppressing Diet, in Pts w/ Adv/Rec Endometrial Cancer
M25-231_GOG-3115 A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRa-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Study of Carboplatin and Mirvetuximab Soravtansine in Subjects With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
MK5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy
MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (Enrollment paused 06Aug2025)
Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemo to Ovarian Function Suppression + Endo Therapy in premenopausal pts w/pN0-1 ER-Positive/HER2-Negative
RLY-2608-102: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
RLY-2608-102: Ph 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant for PIK3CA-mutant (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

Previous Next